M
M. Jebbink
Researcher at Netherlands Cancer Institute
Publications - 9
Citations - 101
M. Jebbink is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Internal medicine & Osimertinib. The author has an hindex of 3, co-authored 4 publications receiving 49 citations.
Papers
More filters
Journal ArticleDOI
The force of HER2 - A druggable target in NSCLC?
TL;DR: In this review HER2 alterations in NSCLC are discussed, including diagnostic challenges and treatment strategies, and three principal mechanisms of Her2 alterations can be identified: HER2 protein overexpression, HER2 gene amplification and Her2 gene mutations.
Journal ArticleDOI
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
Adrianus J. de Langen,Adrianus J. de Langen,M. Jebbink,Sayed M.S. Hashemi,Justine L. Kuiper,J. de Bruin-Visser,Kim Monkhorst,Erik Thunnissen,Egbert F. Smit,Egbert F. Smit +9 more
TL;DR: The relation between response rate and HER2 expression level and copy number suggests effective HER2 targeting by trastuzumab, although the combination with paclitaxel does not allow to determine the relative contribution of the individual drugs in terms of treatment efficacy.
Journal ArticleDOI
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Floris Dammeijer,Cornedine J. de Gooijer,Mandy van Gulijk,Melanie Lukkes,Larissa Klaase,Lysanne A. Lievense,Cynthia Waasdorp,M. Jebbink,Gerben Bootsma,Jos A. Stigt,Bonne Biesma,Margaretha E.H. Kaijen-Lambers,Joanne Mankor,Heleen Vroman,Robin Cornelissen,Paul Baas,Vincent van der Noort,Jacobus A. Burgers,Joachim G.J.V. Aerts +18 more
TL;DR: In this article, the effects of gemcitabine on the immune system were investigated in mesothelioma patients and it was shown that gemcitabiine treatment was associated with an increased NK-cell and decreased Tregulatory cell proliferation whereas the opposite occurred in control patients.
Journal ArticleDOI
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
J.M. van Berge Henegouwen,M. Jebbink,L.R. Hoes,H. van der Wijngaart,Laurien J. Zeverijn,Daphne L. van der Velden,Paul Roepman,Wendy W.J. de Leng,Anne M.L. Jansen,E. van Werkhoven,Vincent van der Noort,Anthonie J. van der Wekken,Adrianus J. de Langen,E. E. Voest,H. M. W. Verheul,Egbert F. Smit,Hans Gelderblom +16 more
TL;DR: In this article , the authors presented the results of the cohort "trastuzumab/pertuzumaab for HER2 exon20 mutation positive (HER2m+) NSCLC".
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
Liesbeth M. Hondelink,M. Jebbink,Jan H. von der Thüsen,Danielle Cohen,Hendrikus J. Dubbink,Marthe S. Paats,Anne-Marie C. Dingemans,Adrianus J. de Langen,Mirjam C. Boelens,Egbert F. Smit,Egbert F. Smit,Pieter E. Postmus,Tom van Wezel,Tom van Wezel,Kim Monkhorst +14 more
TL;DR: In this paper, the authors compared molecular work-up strategies from three hospitals of 161 first or second generation EGFR TKI treated cases and 159 osimertinib treated cases.